- Policy
- Additional indication of interferon or Kaletra is recognized
- by Kim, Jung-Ju Mar 2, 2020 06:20am
- The government recognizes widespread benefits of antiviral drugs even if it is not approved indication, including interferon, as well as AIDS treatments such as Kaletra for the treatment of The Ministry of Health and Welfare issued a partial amendment of 'Details on the Pharmaceutical Reimbursement Listing Standard and Method' on the 20th a
- Policy
- COVID-19 treatment is active in domestic clinical
- by Lee, Tak-Sun Feb 28, 2020 06:02am
- As the number of Korean COVID-19 patients has soared, the development of therapeutics is also active. In addition to multinational pharmaceutical company Gillead, domestic pharmaceutical company Komipharm has applied for clinical trial approval of the pipelines, and Immunemed's antiviral drug was approved for therapeutic use. Gilead said t
- Policy
- A set of three bills about COVID-19 was passed
- by Lee, Jeong-Hwan Feb 28, 2020 06:01am
- The National Assembly held a plenary session at 2 pm on the 26th and passed 'a set of three bills about COVID-19' and a proposal for a special committee for countermeasures against the COVID-19. A set of three bills about COVID-19 came into effect after government promulgation, and the ruling & the opposition parties had the authority to a
- Policy
- What is the solution to the COVID-19 crisis?
- by Lee, Jeong-Hwan Feb 28, 2020 06:01am
- To reduce the number of serious and death patients, the burden on medical institutions should be minimized. Abandoning the idea that a hospital should see a minor patient unconditionally, and dispatching a medical team, but it is possible to efficiently manage infection by securing a management bed of a serious patient. (Professor Jung-sik Eo
- Policy
- Remdesivir to promote domestic clinical trials for COVID-19
- by Lee, Tak-Sun Feb 27, 2020 06:33am
- Gilead developed the Ebola treatment 'Remdesivir' in preparation for a clinical trial in Korea. The MFDS plans to review the Phase III clinical trial plan from Gilead promptly. Eui-Kyung Lee, the Minister of the MFDS explained on the 25th at the regular briefing on the COVID-19 Central Disaster and Safety Headquarters, "COVID-19 drugs a
- Policy
- Betmiga lowers pricing with PVA, Tazime keeps original price
- by Kim, Jung-Ju Feb 27, 2020 06:32am
- Hanmi Pharmaceutical’s bacterial blood infection and meningitis treatment Tazime 2 g injection has been exempted from automatic pricing reduction as its competing item is removed from the tentative reimbursement listing. The price of Astellas Pharma Korea’s blockbuster drug Betmiga PR tablet would be lowered from Mar 1 due to price-volume
- Policy
- National Assembly also shocked by COVID-19
- by Lee, Jeong-Hwan Feb 26, 2020 06:29am
- Parliament and politicians were also shocked by COVID-19. Recently, the plenary session was urgently canceled as the delegation of the debate held at the congress hall in the parliament building was confirmed by COVID-19, and a 24 hour closure measure was established for defense. Representative Jae-cheol Shim and a member Jeon Hee-kyung
- Policy
- Only 6% of domestic medical staff received the vaccines
- by Lee, In-Bok Feb 25, 2020 06:12am
- A large number of university hospital staff in Korea are treating patients without even receiving a preventive vaccine recommended for medical workers. Even 93.5% of administrators for Hospital Infection did not have all the recommended vaccines. As most of the reasons for the difficulty in vaccinating are the cost burden, the government need
- Policy
- Nocdurna SL benefits are newly established
- by Kim, Jung-Ju Feb 25, 2020 06:09am
- The new benefit standard for the pituitary hormone, Nocdurna Sublingual tab (Desmopressin acetate), which is used for the treatment of nocturnal urine, will be applied from next month. However, because The drug’s benefit would be limited to only for idiopathic nocturnal polyuria, and it is not eligible for primary urination and nocturnal
- Policy
- The ruling & opposition parties agreed to COVID-19 committee
- by Lee, Jeong-Hwan Feb 24, 2020 06:27am
- The parliament barely agreed to form a special committee for the COVID-19. It will be officially launched when it is processed at the plenary session on the 24th. The official name was the National Assembly COVID-19 special committee, and the chairman was appointed by the Democratic Party. On the 20th, a member of the Democratic Party, Hud
